Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
Tag Archive for: CDMO
When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Sotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.
Dyadic International Inc. and bYoRNA SAS partnered to advance innovative bioproduction technologies for scaling up the production of therapeutic mRNA from C1-Cells.
Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological drugs advances its international expansion with the opening of its first commercial office in the United States located in Boston, Massachusetts.
Bristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities.
The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Fermatation expert Evonik SE has entered into an agreement with the German recombinant silk producer AMSilk to produce industrial quantities of innovative, sustainable silk proteins.
CB21 Pharma Ltd announces that it entered a global strategic collaboration to combine
its leading expertise and clinical research program in phytocannabinoids with world-class
pharmaceutical strategic consulting and business development services of NorthStar Corporate Finance Ltd and Kru?ger Beteiligungs GmbH, forming a new company called CB21 R&D.